Nutlin-3a induced KRAS mutant lung cancer specific methuosis-like cell death is dependent on GFPT2
Kim, D.; Min, D.; Kim, J.; Kim, M. J.; Seo, Y.; Jung, B. H.; Kwon, S.-H.; Lee, J.-Y.
Show abstract
Oncogenic KRAS mutation, the most frequent mutation in non-small cell lung cancer (NSCLC), is an aggressiveness risk factor and leads to the metabolic reprogramming of cancer cells by promoting glucose, glutamine, and fatty acid absorption and glycolysis. Lately, sotorasib was approved by the FDA as a first-in-class KRAS-G12C inhibitor. However, sotorasib still has a derivative barrier, which is not effective for other KRAS mutation types, except for G12C. Additionally, resistance to sotorasib is likely to develop, demanding the need for alternative therapeutic strategies. In this study, we found that nutlin-3a, an MDM2 antagonist, inhibited the KRAS-PI3K/Akt-mTOR pathway and disrupted the fusion of both autophagosomes and macropinosomes with lysosomes. This further elucidated non-apoptotic and catastrophic macropinocytosis associated methuosis-like cell death, which was found to be dependent on GFPT2 of the hexosamine biosynthetic pathway, specifically in KRAS mutant NSCLC cells. These results indicate the potential of nutlin-3a as an alternative agent for treating KRAS mutant NSCLC cells.
Matching journals
The top 12 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- TAK1-mediated phosphorylation of PLCE1 represses PIP2 hydrolysis to impede esophageal squamous cancer metastasis 95%
- Phosphodiesterase 1A physically interacts with YTHDF2 and reinforces the progression of non-small cell lung cancer 94%
- STAMBPL1 activates the GRHL3/HIF1A/VEGFA axis through interaction with FOXO1 to promote angiogenesis in triple-negative breast cancer 94%
Similar papers in this journal
- SARS-CoV-2-Triggered Mast Cell Rapid Degranulation Induces Alveolar Epithelial Inflammation and Lung Injury 93%
- Cathepsin L plays a key role in SARS-CoV-2 infection in humans and humanized mice and is a promising target for new drug development 93%
- Vertical RAS-pathway inhibition in pancreatic cancer drives therapeutically exploitable mitochondrial alterations 91%
Similar papers in this journal
- Rigosertib promotes anti-tumor immunity via autophagic degradation of PD-L1 in colorectal cancer cells 95%
- Bcl-xL is translocated to the nucleus via CtBP2 to epigenetically promote metastasis 94%
- Tumor-associated macrophages confer resistance to chemotherapy (Trifluridine/Tipiracil) in digestive cancers by overexpressing Thymidine Phosphorylase 93%
Similar papers in this journal
- ORMDL1 is upregulated and associated with favorable outcome in colorectal cancer 94%
- KRAS Inhibition Reverses Chemotherapy Resistance Promoted by Therapy-Induced Senescence-like in Pancreatic Ductal Adenocarcinoma 92%
- A 'one-two punch' therapy strategy to target chemoresistance in estrogen receptor positive breast cancer 92%
Similar papers in this journal
- Tumors cells with mismatch repair deficiency induce hyperactivation of Pyroptosis resistant to cell membrane damage but are more sensitive to Co-treatment of IFN-γ and TNF-α to PANoptosis 96%
- Effect of OASL on OXA-induced immunogenic cell death in gastric cancer via cGAS-STING pathway 94%
- Inhibiting BCKDK in triple-negative breast cancer suppress protein translation, impair mitochondrial function, and potentiate doxorubicin cytotoxicity 94%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.